Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio, Inc.

Analysts are intrested in these 5 stocks: ( ($OTLK) ), ( ($HBAN) ), ( ($CORT) ), ( ($CAPR) ) and ( ($GOSS) ). Here is a breakdown of their recent


OTLK, HBAN, CORT, CAPR, GOSS Trending With Analysts

In a report released today, Laura Chico from Wedbush maintained a Hold rating on Gossamer Bio, with a price target of $1.00. Chico covers the Healt...

Gossamer Bio (GOSS) Receives a Hold from Wedbush

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Summit Therapeutics (SMMT) and Gossamer Bio (GOSS)...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT) and Gossamer Bio (GOSS)

Gossamer Bio ( ($GOSS) ) has issued an announcement. On July 23, 2026, Gossamer Bio terminated its collaboration and license agreement with Chiesi ...

Gossamer Bio Reclaims Seralutinib Rights and Control

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Outlook Therapeutics (OTLK) and Gossamer Bio (GOSS). Outlook Ther...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GOSS	$0.14	+2.21%	6.59M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GOSS	$0.14	+2.2%	6.59M
3
4
5
6

GOSS

Get Gossamer Bio, Inc. Data in Excel

Get Gossamer Bio, Inc. Data in Excel